Erschienen in:

08.04.2016 | Erratum

Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

verfasst von: Evelyn Despierre, Ignace Vergote, Ryan Anderson, Corneel Coens, Dionyssios Katsaros, Fred R. Hirsch, Bram Boeckx, Marileila Varella-Garcia, Annamaria Ferrero, Isabelle Ray-Coquard, John A. Green, Christopher Steer, Els M. J. J. Berns, Antonio Casado, Diether Lambrechts, Antonio Jimeno

Erschienen in: Targeted Oncology | Ausgabe 3/2016